Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus

Journal of Viral Hepatitis

Volumn 13, Issue 7, 2006, Pages 466-473

  Moreno, A ^a,b   Barcena R ^a   Garcia Garzon S ^a   Moreno, L ^a   Quereda, C ^a   Muriel, A ^a   Zamora, J ^a   Mateos, M L ^a   Perez Elias M J ^a   Antela, A ^a   Diz, S ^a   Moreno, S ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cut off; HCV RNA kinetics; Human immunodeficiency virus; Pegylated interferon ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT FAILURE;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV; HIV SEROPOSITIVITY; HUMANS; INTERFERON ALFA-2B; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 33745217423     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00710.x     Document Type: Article

References (29)

1. Fried MW Shiffman ML Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infections. N Engl J Med 2002 347: 975 982.
2. Manns MP McHutchison JG Gordon SC, and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358: 958 965.
3. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Gastroenterology 2002 123: 2082-99.
4. Berg T Sarrazin C Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37: 600 609.
5. Davis GL Wong JB McHutchison JG Manns MP Harvey J Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38: 645 652.
6. Bica I McGovern B Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32: 492 497.
7. Benhamou Y Bochet M Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients. The Multivirc Group. Hepatology 1999 30: 1054 1058.
8. Chung RT Andersen J Volberding P, for the AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. N Engl J Med 2004 351: 451 459.
9. Torriani FJ Rodriguez-Torres M Rockstroh J et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 351: 438 450.
10. Carrat F Bani-Sadr F Pol S et al. ANRS HCO2 RIBAVIC Study Team. Pegylated-interferon-alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized trial. JAMA 2004 292: 2839 2848.
11. Soriano V Puoti M Sulkowski M et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004 18: 1 12.
12. Torriani FJ Ribeiro RM Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003 188: 1498 1507.
13. Hosmer DW Lemeshow S. Applied Logistic Regression. New York, NY, USA: John Wiley & sons, 1989.
14. Belsley DA. Conditioning Diagnostic: Collinearity and Weak Data in Regression. New York, NY, USA: John Wiley & sons, 1991.
15. Zamora J Muriel A Abraira V. SPSS macro syntaxis for collinearity analysis in logistic regression. ftp://ftp.hrc.es/pub/programas/macros/ collinear.SPS.
16. Kim AY Schulze zur Wiesch J Day CL et al. Low Nadir CD4 Counts are Associated with Loss of CD4 T-cell Responses against HCV in HCV+/HIV+ Co-infected Subjects. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004. Abstract 790.
17. Sherman KE O'Brien J Gutierrez AG et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993 31: 2679 2682.
18. Cribier B Rey D Schmitt C Lang JM Kirn A Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995 9: 1131 1136.
19. Bonacini M Govindarajan S Blatt LM Schmid P Conrad A Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV-RNA. J Viral Hepat 1999 6: 203 208.
20. Baba M Pauwels R Balzarni J Herdewijn P De Clerq E Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2'3'-dideoxynucleosides but enhances inhibitory effects of purine 2′3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987 31: 1613 1617.
21. Gries JM Torriani FJ Rodriguez-Torres M et al. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with HCV/HIV Co-infection: Results of a Randomized Clinical Study. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11, 2004. Abstract 136LB.
22. Quereda C Moreno L Moreno A et al. Could HAART Influence the Effectiveness of HCV Treatment in HIV-Infected Patients? 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003. Abstract V-778.
23. Giannini E Risso D Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003 163: 218 224.
24. Giannini E Botta F Fasoli A et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999 44: 1249 1253.
25. Moreno A Quereda C Moreno L et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin. Antiviral Therapy 2004 9: 133 138.
26. Hadziyannis SJ Sette HJ Morgan TR et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140: 346 355.
27. Lindahl K Stahle L Bruchfeld A Swarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005 41: 275 279.
28. Diago M Romero-Gómez M Crespo J et al. Peginterferon Alfa-2a (40 KD) (PEGASYS®) and Ribavirin (COPEGUS®) in Patients Infected with Hepatitis C virus (HCV) Genotype 1 who Failed to Respond to Interferon Alfa and Ribavirin: Final Results of the Spanish High Dose Induction Pilot Trial [Abstract 522]. In: Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. October 29-November 2, 2004, Boston, MA, USA.
29. Buti M Valdés A Sánchez-Avila F Esteban R Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003 37: 1226 1227.